Clinical trial
INNO-105 in Patients With Solid Tumors
NCT00255333 · Innovive Pharmaceuticals, Industry · Terminated
Key facts
| NCT number | NCT00255333 |
|---|---|
| Title | INNO-105 in Patients With Solid Tumors |
| Official title | A Phase I, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Weekly Intravenous INNO-105 in Adult Patients With Advanced Solid Malignancies |
| Lead sponsor | Innovive Pharmaceuticals, Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Tumors |
| Intervention type | Drug |
| Interventions | INNO-105 |
| Enrollment | 24 |
| Start date | Nov 1, 2005 |
| Completion | Mar 1, 2007 |
| First posted | Nov 18, 2005 |
| Last update posted | May 14, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: